Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Photocure ASA ( (PHCUF) ) just unveiled an update.
Photocure ASA reported strong financial performance in Q3 2025, with revenues of NOK 134.1 million and an EBITDA of NOK 10.2 million. The company is expanding its blue light cystoscopy technology in the U.S. and Europe, and has partnered with Intelligent Scopes Corporation to develop AI software for improved bladder cancer diagnostics. This partnership aims to secure FDA clearance and enhance Photocure’s market position, potentially driving further growth and shareholder value.
More about Photocure ASA
Photocure ASA, headquartered in Oslo, Norway, is a company focused on delivering transformative solutions for bladder cancer patients. Their unique technology enhances cancer cell visibility, improving patient outcomes. Photocure is listed on the Oslo Stock Exchange.
Average Trading Volume: 51,448
Current Market Cap: NOK1.38B
Learn more about PHCUF stock on TipRanks’ Stock Analysis page.